Barely Significant
← all excerpts

Enhanced Tumor-to-Background Contrast with [<sup>52</sup>Mn]Mn-BPPA-Bevacizumab VEGF-Targeted Immuno-PET in Cervical Cancer.

Pharmaceuticals (Basel) · 2026 · PMC13028754 · PMID 41901362

Europe PMCDOI
2
hedged sentences
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp < 0.0001actually significant
Tumor-to-blood ratios increased significantly over time for both tracers; however, [ 52 Mn]Mn-BPPA-bevacizumab demonstrated significantly higher ratios from day 2 onward, with the difference becoming highly significant at days 3, 5, 7, and 10 ( p < 0.0001).

also in 132,142 other papers

did not reach statistical significanceno p-value reported
Although a more sustained and slightly higher average tumor uptake was observed with [ 52 Mn]Mn-BPPA-bevacizumab compared with the previously reported [ 52 Mn]Mn-DOTAGA-bevacizumab [ 15 ], the difference in absolute tumor uptake did not reach statistical significance at any measured time point.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.